Merops Switch to
Peptidases

Inhibitor

Family Clan Small-molecule
inhibitor SEARCHES BLAST
MEROPS

Other
information

Literature for ritonavir (A02.001 inhibitor)

Summary Structure Literature

(Topics flags: S Structure, I Inhibitor, V Review. To select only the references relevant to a single topic, click the link above. See explanation.)

    2017
  1. Huang,Y.M., Raymundo,M.A., Chen,W. and Chang,C.A.
    Mechanism of the association pathways for a pair of fast and slow binding ligands of HIV-1 protease
    Biochemistry56, 1311-1323. PubMed  Europe PubMed DOI  I
    2. 2013
  2. Keliher,E.J., Reiner,T., Earley,S., Klubnick,J., Tassa,C., Lee,A.J., Ramaswamy,S., Bardeesy,N., Hanahan,D., DePinho,R.A., Castro,C.M. and Weissleder,R.
    Targeting cathepsin E in pancreatic cancer by a small molecule allows in vivo detection
    Neoplasia15, 684-693. PubMed  Europe PubMed DOI  I
  3. Liu,Z., Yedidi,R.S., Wang,Y., Dewdney,T.G., Reiter,S.J., Brunzelle,J.S., Kovari,I.A. and Kovari,L.C.
    Insights into the mechanism of drug resistance: X-ray structure analysis of multi-drug resistant HIV-1 protease ritonavir complex
    Biochem Biophys Res Commun431, 232-238. PubMed  Europe PubMed DOI  S  I
    4. 2012
  4. Santos,J.R., Llibre,J.M., Imaz,A., Domingo,P., Iribarren,J.A., Marino,A., Miralles,C., Galindo,M.J., Ornelas,A., Moreno,S., Schapiro,J.M. and Clotet,B.
    Mutations in the protease gene associated with virological failure to lopinavir/ritonavir-containing regimens
    J Antimicrob Chemother67, 1462-1469. PubMed  Europe PubMed DOI  I
    5. 2011
  5. Olajuyigbe,F., Demitri,N. and Geremia,S.
    Investigation of 2-fold disorder of inhibitors and relative potency by crystallizations of HIV-1 protease in ritonavir and saquinavir mixtures
    Cryst Growth Des11, 4378-4385. DOI  I
    6. 2010
  6. Dirauf,P., Meiselbach,H. and Sticht,H.
    Effects of the V82A and I54V mutations on the dynamics and ligand binding properties of HIV-1 protease
    J Mol Model16, 1577-1583. PubMed  Europe PubMed DOI  I
    7. 2008
  7. Nukoolkarn,V., Lee,V.S., Malaisree,M., Aruksakulwong,O. and Hannongbua,S.
    Molecular dynamic simulations analysis of ritonavir and lopinavir as SARS-CoV 3CL(pro) inhibitors
    J Theor Biol254, 861-867. PubMed  Europe PubMed DOI  I
  8. Purohit,R., Rajasekaran,R., Sudandiradoss,C., George Priya Doss,C., Ramanathan,K. and Rao,S.
    Studies on flexibility and binding affinity of Asp25 of HIV-1 protease mutants
    Int J Biol Macromol42, 386-391. PubMed  Europe PubMed DOI  I
    9. 2006
  9. Andrews,K.T., Fairlie,D.P., Madala,P.K., Ray,J., Wyatt,D.M., Hilton,P.M., Melville,L.A., Beattie,L., Gardiner,D.L., Reid,R.C., Stoermer,M.J., Skinner-Adams,T., Berry,C. and McCarthy,J.S.
    Potencies of human immunodeficiency virus protease inhibitors in vitro against Plasmodium falciparum and in vivo against murine malaria
    Antimicrob Agents Chemother50, 639-648. PubMed  Europe PubMed DOI  I
  10. Aruksakunwong,O., Wolschann,P., Hannongbua,S. and Sompornpisut,P.
    Molecular dynamic and free energy studies of primary resistance mutations in HIV-1 protease-ritonavir complexes
    J Chem Inf Model46, 2085-2092. PubMed  Europe PubMed DOI  I
  11. Mastrolorenzo,A., Rusconi,S., Scozzafava,A. and Supuran,C.T.
    Inhibitors of HIV-1 protease: 10 years after
    Expert Opin Ther Pat16, 1067-1091. DOI  V  I
    12. 2005
  12. Kaplan,S.S. and Hicks,C.B.
    Lopinavir/ritonavir in the treatment of human immunodeficiency virus infection
    Expert Opin Pharmacother6, 1573-1585. PubMed  Europe PubMed DOI  I
    13. 2004
  13. [YEAR:28-9-2004]Clemente,J.C., Moose,R.E., Hemrajani,R., Whitford,L.R., Govindasamy,L., Reutzel,R., McKenna,R., Agbandje-McKenna,M., Goodenow,M.M. and Dunn,B.M.
    Comparing the accumulation of active- and nonactive-site mutations in the HIV-1 protease
    Biochemistry43, 12141-12151. PubMed  Europe PubMed DOI  S  I
  14. de Mendoza,C. and Soriano,V.
    Resistance to HIV protease inhibitors: mechanisms and clinical consequences
    Curr Drug Metab5, 321-328. PubMed  Europe PubMed DOI  I
    15. 2001
  15. [YEAR:30-8-2001]Hosseini,H., Andre,P., Lefevre,N., Viala,L., Walzer,T., Peschanski,M. and Lotteau,V.
    Protection against experimental autoimmune encephalomyelitis by a proteasome modulator
    J Neuroimmunol118, 233-244. PubMed  Europe PubMed DOI  I
  16. Pichova,I., Pavlickova,L., Dostal,J., Dolejsi,E., Hruskova-Heidingsfeldova,O., Weber,J., Ruml,T. and Soucek,M.
    Secreted aspartic proteases of Candida albicans, Candida tropicalis, Candida parapsilosis and Candida lusitaniae. Inhibition with peptidomimetic inhibitors
    Eur J Biochem268, 2669-2677. PubMed  Europe PubMed DOI  I
  17. Qari,S.H., Magre,S., Garcia-Lerma,J.G., Hussain,A.I., Takeuchi,Y., Patience,C., Weiss,R.A. and Heneine,W.
    Susceptibility of the porcine endogenous retrovirus to reverse transcriptase and protease inhibitors
    J Virol75, 1048-1053. PubMed  Europe PubMed DOI  I
    18. 2000
  18. [YEAR:3-10-2000]Todd,M.J., Luque,I., Velazquez-Campoy,A. and Freire,E.
    Thermodynamic basis of resistance to HIV-1 protease inhibition: calorimetric analysis of the V82F/I84V active site resistant mutant
    Biochemistry39, 11876-11883. PubMed  Europe PubMed DOI  I
    19. 1999
  19. Borg-von Zepelin,M., Meyer,I., Thomssen,R., Wurzner,R., Sanglard,D., Telenti,A. and Monod,M.
    HIV-protease inhibitors reduce cell adherence of Candida albicans strains by inhibition of yeast secreted aspartic proteases
    J Invest Dermatol113, 747-751. PubMed  Europe PubMed DOI  I
  20. Gruber,A., Berlit,J., Speth,C., Lass-Florl,C., Kofler,G., Nagl,M., Borg-von Zepelin,M., Dierich,M.P. and Wurzner,R.
    Dissimilar attenuation of Candida albicans virulence properties by human immunodeficiency virus type 1 protease inhibitors
    Immunobiology201, 133-144. PubMed  Europe PubMed DOI  I
  21. Monod,M., Borg-von Zepelin,M., Telenti,A. and Sanglard,D.
    The inhibition of Candida-albicans-secreted aspartic proteases by three different HIV protease inhibitors
    Dermatology198, 412-414. PubMed  Europe PubMed  I
  22. [YEAR:10-12-1999]Schmidtke,G., Holzhutter,H.G., Bogyo,M., Kairies,N., Groll,M., De Giuli,R., Emch,S. and Groettrup,M.
    How an inhibitor of the HIV-I protease modulates proteasome activity
    J Biol Chem274, 35734-35740. PubMed  Europe PubMed DOI  I
    23. 1998
  23. [YEAR:12-2-1998]Kempf,D.J., Sham,H.L., Marsh,K.C., Flentge,C.A., Betebenner,D., Green,B.E., McDonald,E., Vasavanonda,S., Saldivar,A., Wideburg,N.E., Kati,W.M., Ruiz,L., Zhao,C., Fino,L., Patterson,J., Molla,A., Plattner,J.J. and Norbeck,D.W.
    Discovery of ritonavir, a potent inhibitor of HIV protease with high oral bioavailability and clinical efficacy
    J Med Chem41, 602-617. PubMed  Europe PubMed DOI  I
  24. [YEAR:8-12-1998]Towler,E.M., Gulnik,S.V., Bhat,T.N., Xie,D., Gustschina,E., Sumpter,T.R., Robertson,N., Jones,C., Sauter,M., Mueller-Lantzsch,N., Debouck,C. and Erickson,J.W.
    Functional characterization of the protease of human endogenous retrovirus, K10: can it complement HIV-1 protease?
    Biochemistry37, 17137-17144. PubMed  Europe PubMed DOI  I
  25. Wlodawer,A. and Vondrasek,J.
    Inhibitors of HIV-1 protease: a major success of structure-assisted drug design
    Annu Rev Biophys Biomol Struct27, 249-284. PubMed  Europe PubMed DOI  V  I
    26. 1997
  26. Cornelissen,M., van den Burg,R., Zorgdrager,F., Lukashov,V. and Goudsmit,J.
    pol gene diversity of five human immunodeficiency virus type 1 subtypes: evidence for naturally occurring mutations that contribute to drug resistance, limited recombination patterns, and common ancestry for subtypes B and D
    J Virol71, 6348-6358. PubMed  Europe PubMed  I
    27. 1995
  27. [YEAR:28-3-1995]Kempf,D.J., Marsh,K.C., Denissen,J.F., McDonald,E., Vasavanonda,S., Flentge,C.A., Green,B.E., Fino,L., Park,C.H. and Kong,X.P.
    ABT-538 is a potent inhibitor of human immunodeficiency virus protease and has high oral bioavailability in humans
    Proc Natl Acad Sci U S A92, 2484-2488. PubMed  Europe PubMed DOI  I

feedback
Page created 8-September-2023

EMBL-EBI logo

© 2025 EBI
Terms of use